Payment overview · 2025
General Payments
$1,741.66
101 reported records · 18 companies
Healthcare provider profile · identity verified
Naeemuddin Jatoi, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine · DECATUR, IL · NPI 1922070333
Verified facts
What the public records show
CMS Open Payments records show Naeemuddin Jatoi, M.D. received $1,741.66 in general payments during 2025 across 101 reported records.
Amgen Inc. accounted for 16.6% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 29 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Farxiga, Jardiance, Ozempic.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 19 claims for Synthroid by this doctor in 2024.
Astellas Pharma US Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Myrbetriq as an associated drug or biological on 16 records involving 16 distinct recipient NPIs. Public Medicare Part D data also shows 38 claims for Myrbetriq by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 37 claims for Farxiga by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 51 claims for Jardiance by this doctor in 2024.
E.R. Squibb & Sons, L.L.C. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 27956 records involving 14870 distinct recipient NPIs. Public Medicare Part D data also shows 170 claims for Eliquis by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 19 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 51 claims for Jardiance by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 41 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Rybelsus by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 170 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Amgen Inc. | Unresolved — no canonical attribution shown | $289.21 | 16.6% | 16 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $283.90 | 16.3% | 16 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $224.36 | 12.9% | 19 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $184.17 | 10.6% | 11 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $184.11 | 10.6% | 10 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $108.55 | 6.2% | 6 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $86.04 | 4.9% | 3 | 2025 |
| Verona Pharma, Inc. | Unresolved — no canonical attribution shown | $63.32 | 3.6% | 4 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $56.80 | 3.3% | 2 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $53.92 | 3.1% | 3 | 2025 |
| Almatica Pharma LLC | Unresolved — no canonical attribution shown | $35.99 | 2.1% | 2 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $34.85 | 2.0% | 2 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $30.04 | 1.7% | 2 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $29.21 | 1.7% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $21.47 | 1.2% | 1 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $20.70 | 1.2% | 1 | 2025 |
| E.R. Squibb & Sons, L.L.C. | Unresolved — no canonical attribution shown | $18.37 | 1.1% | 1 | 2025 |
| Neurocrine BioSciences, Inc. | Unresolved — no canonical attribution shown | $16.65 | 1.0% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,741.66 | 101 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $184.11 | 10 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $171.69 | 10 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $146.98 | 9 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $144.37 | 8 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $142.23 | 7 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $137.09 | 8 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $107.40 | 12 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $86.04 | 3 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $85.41 | 5 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $81.11 | 5 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $78.19 | 4 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $71.35 | 4 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $69.32 | 4 | 2025 |
Source payment records
|
|||||
| Ohtuvayre Normalized: ohtuvayre |
Drug | Verona Pharma, Inc. | $63.32 | 4 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $58.98 | 3 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | E.R. Squibb & Sons, L.L.C., PFIZER INC. | $58.11 | 3 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc. | $56.80 | 2 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $53.92 | 3 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $53.92 | 3 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $47.79 | 3 | 2025 |
Source payment records
|
|||||
| KISUNLA Normalized: kisunla |
Drug | Lilly USA, LLC | $39.23 | 2 | 2025 |
Source payment records
|
|||||
| LOREEV XR Normalized: loreev xr |
Drug | Almatica Pharma LLC | $35.99 | 2 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $34.85 | 2 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $30.04 | 2 | 2025 |
Source payment records
|
|||||
| Veozah Normalized: veozah |
Drug | Astellas Pharma US Inc | $29.21 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $21.47 | 1 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $20.70 | 1 | 2025 |
Source payment records
|
|||||
| BEXSERO Normalized: bexsero |
Biological | GlaxoSmithKline, LLC. | $17.82 | 1 | 2025 |
Source payment records
|
|||||
| INGREZZA Normalized: ingrezza |
Drug | Neurocrine BioSciences, Inc. | $16.65 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 170 | exact normalized | Medicare Part D |
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 37 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 51 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 41 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
19 | suppressed by CMS |
| Astellas Pharma US Inc Exact reporting entity; no affiliate inference |
2025 | Myrbetriq open payments reported associated product |
CMS Open Payments — General Payments 16 supporting records · 16 recipient NPIs · example record 1238599014 |
Myrbetriq · 2024 Exact normalized brand match · 1 Part D row |
38 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
37 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
51 | 16 |
| E.R. Squibb & Sons, L.L.C. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 27956 supporting records · 14870 recipient NPIs · example record 1184377713 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
170 | 30 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
19 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
51 | 16 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
41 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
170 | 30 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 644 | 198 |
| Amlodipine Besylate | Amlodipine Besylate | 529 | 174 |
| Levothyroxine Sodium | Levothyroxine Sodium | 491 | 127 |
| Metoprolol Succinate | Metoprolol Succinate | 449 | 138 |
| Lisinopril | Lisinopril | 345 | 107 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 336 | 106 |
| Pantoprazole Sodium | Pantoprazole Sodium | 335 | 105 |
| Losartan Potassium | Losartan Potassium | 271 | 78 |
| Metformin Hcl | Metformin Hcl | 246 | 79 |
| Tramadol Hcl | Tramadol Hcl | 243 | 63 |
| Hydrochlorothiazide | Hydrochlorothiazide | 239 | 78 |
| Omeprazole | Omeprazole | 227 | 72 |
| Gabapentin | Gabapentin | 220 | 69 |
| Potassium Chloride | Potassium Chloride | 220 | 75 |
| Carvedilol | Carvedilol | 219 | 71 |
| Tamsulosin Hcl | Tamsulosin Hcl | 215 | 70 |
| Furosemide | Furosemide | 211 | 69 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 181 | 58 |
| Montelukast Sodium | Montelukast Sodium | 173 | 61 |
| Eliquis | Apixaban | 170 | 30 |
| Simvastatin | Simvastatin | 170 | 50 |
| Allopurinol | Allopurinol | 153 | 44 |
| Pravastatin Sodium | Pravastatin Sodium | 138 | 43 |
| Clopidogrel | Clopidogrel Bisulfate | 135 | 50 |
| Metoprolol Tartrate | Metoprolol Tartrate | 135 | 48 |
| Glimepiride | Glimepiride | 125 | 36 |
| Trazodone Hcl | Trazodone Hcl | 125 | 34 |
| Ipratropium Bromide | Ipratropium Bromide | 106 | 66 |
| Nifedipine Er | Nifedipine | 100 | 26 |
| Metformin Hcl Er | Metformin Hcl | 97 | 30 |
| Duloxetine Hcl | Duloxetine Hcl | 96 | 31 |
| Sertraline Hcl | Sertraline Hcl | 96 | 30 |
| Zolpidem Tartrate | Zolpidem Tartrate | 88 | 14 |
| Meloxicam | Meloxicam | 77 | 31 |
| Prednisone | Prednisone | 76 | 59 |
| Torsemide | Torsemide | 74 | 31 |
| Oxybutynin Chloride | Oxybutynin Chloride | 72 | 18 |
| Atenolol | Atenolol | 70 | 22 |
| Fluticasone Propionate | Fluticasone Propionate | 70 | 28 |
| Amitriptyline Hcl | Amitriptyline Hcl | 66 | 22 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 65 | 25 |
| Alprazolam | Alprazolam | 62 | 16 |
| Alendronate Sodium | Alendronate Sodium | 60 | 15 |
| Citalopram Hbr | Citalopram Hydrobromide | 59 | 20 |
| Breo Ellipta | Fluticasone/Vilanterol | 58 | 12 |
| Finasteride | Finasteride | 56 | 16 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 55 | 44 |
| Warfarin Sodium | Warfarin Sodium | 54 | 12 |
| Escitalopram Oxalate | Escitalopram Oxalate | 53 | 15 |
| Buspirone Hcl | Buspirone Hcl | 51 | suppressed |
| Jardiance | Empagliflozin | 51 | 16 |
| Azelastine Hcl | Azelastine Hcl | 48 | 16 |
| Clonidine Hcl | Clonidine Hcl | 47 | 16 |
| Fluoxetine Hcl | Fluoxetine Hcl | 47 | 11 |
| Lovastatin | Lovastatin | 46 | 11 |
| Ropinirole Hcl | Ropinirole Hcl | 44 | 11 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 43 | 14 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 43 | 12 |
| Spironolactone | Spironolactone | 43 | 13 |
| Clonazepam | Clonazepam | 42 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 42 | 17 |
| Ezetimibe | Ezetimibe | 41 | 13 |
| Famotidine | Famotidine | 41 | 19 |
| Ozempic | Semaglutide | 41 | suppressed |
| Pregabalin | Pregabalin | 41 | 12 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 39 | 13 |
| Celecoxib | Celecoxib | 38 | 17 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 38 | 14 |
| Myrbetriq | Mirabegron | 38 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 37 | suppressed |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 37 | 14 |
| Mirtazapine | Mirtazapine | 37 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 37 | 24 |
| Valsartan | Valsartan | 37 | 11 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 35 | suppressed |
| Azithromycin | Azithromycin | 34 | 32 |
| Xarelto | Rivaroxaban | 33 | 12 |
| Cephalexin | Cephalexin | 31 | 23 |
| Donepezil Hcl | Donepezil Hcl | 30 | 11 |
| Propranolol Hcl | Propranolol Hcl | 30 | 14 |
| Tizanidine Hcl | Tizanidine Hcl | 30 | 15 |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 29 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 29 | 23 |
| Lactulose | Lactulose | 29 | 17 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 29 | 25 |
| Bupropion Xl | Bupropion Hcl | 27 | suppressed |
| Fenofibrate | Fenofibrate | 27 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 27 | suppressed |
| Calcitriol | Calcitriol | 26 | suppressed |
| Glipizide Er | Glipizide | 26 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 26 | 12 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 25 | 11 |
| Memantine Hcl | Memantine Hcl | 25 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 24 | 17 |
| Klor-Con M10 | Potassium Chloride | 23 | suppressed |
| Chlorthalidone | Chlorthalidone | 22 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 22 | 11 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 21 | suppressed |
| Lorazepam | Lorazepam | 21 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 21 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 21 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 19 | 18 |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 19 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 19 | suppressed |
| Cefdinir | Cefdinir | 19 | 17 |
| Cholestyramine | Cholestyramine (With Sugar) | 19 | 11 |
| Synthroid | Levothyroxine Sodium | 19 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 19 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 19 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 19 | 11 |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 18 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 18 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 17 | suppressed |
| Carbamazepine | Carbamazepine | 17 | suppressed |
| Incruse Ellipta | Umeclidinium Bromide | 17 | suppressed |
| Nystatin | Nystatin | 17 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 16 | suppressed |
| Klor-Con M20 | Potassium Chloride | 16 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 16 | suppressed |
| Alfuzosin Hcl Er | Alfuzosin Hcl | 15 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 15 | suppressed |
| Fluconazole | Fluconazole | 15 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 15 | suppressed |
| Ketoconazole | Ketoconazole | 15 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 15 | suppressed |
| Spiriva Respimat | Tiotropium Bromide | 15 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 15 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 14 | suppressed |
| Clotrimazole | Clotrimazole | 14 | suppressed |
| Glipizide | Glipizide | 14 | suppressed |
| Novolog Flexpen | Insulin Aspart | 14 | suppressed |
| Rizatriptan | Rizatriptan Benzoate | 14 | suppressed |
| Verapamil Er | Verapamil Hcl | 14 | suppressed |
| Baclofen | Baclofen | 13 | suppressed |
| Colchicine | Colchicine | 13 | suppressed |
| Estradiol | Estradiol | 13 | suppressed |
| Eszopiclone | Eszopiclone | 13 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 13 | suppressed |
| Levofloxacin | Levofloxacin | 13 | 13 |
| Probenecid | Probenecid | 13 | suppressed |
| Sucralfate | Sucralfate | 13 | suppressed |
| Topiramate | Topiramate | 13 | suppressed |
| Advair Hfa | Fluticasone Propion/Salmeterol | 12 | suppressed |
| Humulin 70/30 Kwikpen | Insulin Nph Hum/Reg Insulin Hm | 12 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 12 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 12 | suppressed |
| Rybelsus | Semaglutide | 12 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 11 | suppressed |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 11 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 11 | suppressed |
| Metronidazole | Metronidazole | 11 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,741.66 · 101 records | Amgen Inc. | AIRSUPRA, AREXVY, BEXSERO, BREZTRI, Cologuard Collection Kit, ELIQUIS, EVENITY, FARXIGA, FREESTYLE LIBRE 3, INGREZZA, JARDIANCE, KISUNLA, LEQVIO, LOREEV XR, MOUNJARO, NURTEC ODT, OTEZLA, Ohtuvayre, Ozempic, QULIPTA, REPATHA, REXULTI, SHINGRIX, UBRELVY, VOQUEZNA, Veozah, Wegovy, ZAVZPRET, ZEPBOUND | 10 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error